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Abstract
Aims/hypothesis Patients with severe gain-of-function
mutations in the Kir6.2 subunit of the ATP-sensitive potas-
sium (KATP) channel, have neonatal diabetes, muscle hypo-
tonia and mental and motor developmental delay—a
condition known as iDEND syndrome. However, despite
t h ef a c tt h a tK i r 6 . 2f o r m st h ep o r eo ft h ec a r d i a cK ATP
channel, patients show no obvious cardiac symptoms. The
aim of this project was to use a mouse model of iDEND
syndrome to determine whether iDEND mutations affect
cardiac function and cardiac KATP channel ATP sensitivity.
Methods We performed patch-clamp and in vivo cine-MRI
studies on mice in which the most common iDEND
mutation (Kir6.2-V59M) was targeted to cardiac muscle
using Cre-lox technology (m-V59M mice).
Results Patch-clamp studies of isolated cardiac myocytes
revealed a markedly reduced KATP channel sensitivity to
MgATPinhibitioninm-V59Mmice(IC5062μmol/lcompared
with 13 μmol/l for littermate controls). In vivo cine-MRI
revealed there were no gross morphological differences and
no differences in heart rate, end diastolic volume, end systolic
volume, stroke volume, ejection fraction, cardiac output or
wall thickening between m-V59M and control hearts, either
under resting conditions or under dobutamine stress.
Conclusions/interpretation The common iDEND mutation
Kir6.2-V59M decreases ATP block of cardiac KATP chan-
nels but was without obvious effect on heart function, sug-
gesting that metabolic changes fail to open the mutated
channel to an extent that affects function (at least in the
absence of ischaemia). This may have implications for the
choice of sulfonylurea used to treat neonatal diabetes.
Keywords ATP-sensitivepotassiumchannel.Cardiac
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Introduction
Gain-of-function mutations in either KCNJ11 or ABCC8,
which encode the pore-forming (Kir6.2) and regulatory
(SUR1) subunits of the ATP-sensitive potassium (KATP)
channel, are a common cause of neonatal diabetes, a rare
inherited disorder characterised by the development of dia-
betes within the first 6 months of life [1–5]. In addition to
diabetes, about 20% of patients experience neurological
problems, such as motor and mental developmental delay,
and muscle hypotonia, a condition now known as interme-
diate DEND (iDEND) syndrome [3, 6]. A very few (<3%)
also suffer from epilepsy.
This diverse spectrum of symptoms arises because KATP
channels are present in multiple tissues, where they play
important physiological roles by coupling cell metabolism
to the electrical excitability of the plasma membrane [5,
7–9]. Metabolically induced changes in channel activity
are produced by altered intracellular adenine nucleotide con-
centrations, with ATP inhibiting and MgADP (and MgATP)
stimulating channel activity [9–12]. All KATP channel muta-
tions causing neonatal diabetes examined to date impair the
ability of MgATP to close the channel, thereby suppressing
electrical excitability and cell function. In pancreatic beta
cells, for example, KATP channels link changes in blood glu-
cose concentration to insulin secretion [13]. When blood
glucose,andthusbetacellmetabolism,are lowKATP channels
are open. This maintains the membrane potential at a hyper-
polarised level and dampens down electrical activity, switch-
ing off insulin secretion. An increase in metabolic activity
closesKATP channels,depolarisingthebetacellandincreasing
electricalactivityandinsulinrelease.Neonataldiabetesresults
when mutant KATP channels fail to close in response to eleva-
tion of blood glucose [2–5, 14, 15].
KATP channels also influence the electrical excitability of
many different types of neuron, and impaired neuronal
electrical activity likely underlies the neurological pheno-
type of iDEND patients. Indeed, recent studies suggest that
the muscle hypotonia found in iDEND patients is also a
consequence of the presence of mutant KATP channels in
neuronal tissue [16].
As in endocrine and neuronal cells, Kir6.2 serves as the
pore-forming subunit of cardiac KATP channels, raising the
possibility that gain-of-function mutations in KCNJ11 might
affect cardiac function. Both the sulfonylurea receptors
SUR1 and SUR2A (encoded by ABCC8 and ABCC9, re-
spectively) are present in the heart, and pharmacological
studies and studies of knockout animals suggest that
Kir6.2/SUR2A forms the ventricular KATP channel [17–19]
and Kir6.2/SUR1 the atrial KATP channel [20]. Despite the
fact that KATP channels were first identified in cardiac myo-
cytes [21], where they are found at high density, their
functional role in the heart is less well understood than in
other tissues [7]. Under normal conditions, ventricular KATP
channels appear to be closed and do not contribute to the
normal excitability of the heart. Instead, they are thought to
play a protective role during severe metabolic stress, when
opening of KATP channels leads to action potential shorten-
ing and contractile failure, thereby conserving cellular ATP
levels [22]. Compelling evidence of the importance of
KIR6.2/SUR2A channels in cardiac stress comes from stud-
ies of knockout mice (Kcnj11
−/− and Sur2
–/–) where action
potential shortening in response to anoxia is absent, and
both ischaemic and pharmacological preconditioning are
not observed [19, 23]. Mice lacking KATP channels also
show abnormal vulnerability to a variety of other physiolog-
icalandpathologicalstressesincludingsympatheticsurge[24,
25], physical exertion [26], mineralocorticoid-induced hyper-
tension [27] and volume and pressure overload [26, 28]. In
atrial cells, Kir6.2/SUR1 channels may potentially contribute
to the control of action potential frequency and heart rate.
These data therefore raise the question of whether gain-
of-function mutations in KCNJ11 that cause human neonatal
diabetes might affect cardiac function: for example, by
affecting heart rate or increasing stress tolerance. Indeed,
pharmacological activation of KATP channels with pinacidil
enhanced arrhythmogenicity in tissue isolated from human
hearts [29]. Strikingly, a transgenic mouse selectively over-
expressing two Kir6.2 gain-of-function mutations (an N-
terminal deletion of 30 amino acids and a K185Q point
mutation; ΔN30,K185Q mice) in the heart showed no gross
physiological or morphological cardiac problems [30, 31].
Electrocardiograms were normal, although there was a
slight reduction in the mean 24 h heart rate. Unexpectedly,
isolated myocyte experiments revealed that, despite a 40-
fold reduction in ATP sensitivity, the channel remained
largely closed in intact cells and action potential duration
was unaffected [31]. This was in marked contrast to the
effects of a similar transgene expressed in pancreatic beta
cells, which produced a severe diabetic phenotype [15].
However, in contrast to hearts from control animals, β-
adrenergic stimulation did not cause a positive ionotropic
response in isolated, perfused transgenic hearts, and transgen-
ic hearts also exhibited a higher left ventricular devel-
oped pressure under resting conditions [32].
The extent to which these mice mimic the phenotype of
human neonatal diabetes is, however, unclear. All patients
with neonatal diabetes caused by KCNJ11 mutations are
heterozygotes and increased KATP channel density is not
expected, whereas the transgenic mice strongly overexpress
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mutant KATP channels. In addition, as the transgene was not
targeted to a specific location in the genome, it might have
disrupted an endogenous gene. Further, most studies of
these mice were conducted ex vivo using isolated, perfused
hearts and studies of in vivo cardiac function were limited.
To date, there have been no reports of cardiac abnormalities
in neonatal diabetes patients, but it is unclear whether the
effects of cardiac stress have been examined. In this paper,
we therefore explore the effect that a human mutation causing
neonatal diabetes (Kir6.2-V59M) has on the in vivo function
of the heart. We chose this mutation as it is the most common
mutation causing iDEND syndrome [3].
Methods
Generation of m-V59M mice
Mice expressing Kir6.2-V59M in heart and skeletal muscle
tissue (m-V59M mice) were generated using a Cre-lox ap-
proach. The Kcnj11 gene encoding a mutant Kir6.2-V59M
subunit, preceded by a loxP-flanked STOP sequence and
followed by an FRT-flanked internal ribosome entry site
followed by a GFP cassette, was targeted to the ROSA26
locus to ensure that a single copy of the mutant gene was
expressed from a known location [14]. The endogenous
ROSA promoter was used to prevent excess gene expression.
To generate mice that express the transgene specifically in
muscle tissue, ROSA26StopKir6.2-V59M
lox/+ mice (ROSA
mice) were crossed with mice expressing Cre recombinase
under the control of the muscle creatine kinase promoter
(Mck-Cre mice) [33]. The latter were kindly provided by J.
Brüning (Institute of Genetics, Cologne, Germany). This gen-
erated mice (m-V59M mice) in which expression of Cre
recombinase in heart and skeletal muscle leads to deletion of
the STOP cassette and thus to expression of the mutant gene
encoding Kir6.2-V59M [14]. Wild-type (WT), Mck-Cre and
ROSAlittermateswereusedascontrols.Allexperimentswere
carried out on 12-week-old mice.
Animal care
All experiments were conducted in accordance with the UK
Animals Scientific Procedures Act (1986) and University of
Oxford ethical guidelines. Mice were housed in same-sex
littermate groups of two to eight, in a temperature- and
humidity-controlled room on a 12 h light/dark cycle (lights
on at 06:00 hours). Regular chow food (Teklad Global
2019; Harlan Teklad Global Diet, Blackthorn, UK) con-
taining 55% carbohydrate, 19% protein and 9% fat was
freely available. Mice had ad libitum access to water at
all times. Genotypes were identified by PCR using
genomic DNA isolated from ear biopsies, as previously
described [16].
Molecular biology
RNA extraction and cDNA synthesis Muscle and brain tis-
sues were isolated fromm-V59Mand control mice, immersed
in RNALater solution (Qiagen, Crawley, UK), kept at 4°C for
1 h and thereafter stored at −80°C until ready to process. Total
RNA was extracted from 30 mg of tissue using an RNeasy
Mini Kit (Qiagen), including an on-column DNase digestion
step to remove traces of genomic DNA. RNA concentration
was determined using a NanoDrop ND-1000 spectrophotom-
eter (Thermo Scientific, Wilmington, USA), and its integrity
verified with an Agilent Bioanalyzer (Agilent, South Queens-
ferry, UK). Total RNA, 1 μg, was reverse transcribed in a
20 μl final volume using the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Warrington, UK). An-
other sample of total RNA, 1 μg, was processed identically,
but with no reverse transcriptase present (non-RTcontrol).
Semi-quantitative PCR Mouse Kcnj11 transcript was ampli-
fied by PCR using cDNA prepared from muscle and brain
tissues from m-V59M and control mice, as previously de-
scribed [16]. PCR products were digested with BtsCI (New
England Biolabs, Hitchin, UK) for ∼2 h at 50°C. Digested
PCR fragments were visualised on an agarose gel with ethi-
dium bromide.
Quantitative RT-PCR All cDNA samples were diluted to
4n g / μl with nuclease-free water (Sigma Aldrich, Poole,
U K ) .E a c hr e a c t i o nc o n s i s t e do f5μl (20 ng) cDNA,
12.5 μl 2*PowerSYBR Green I Master Mix (Applied Bio-
systems), 0.75 μlo f1 0μmol/l forward and reverse primers
(300 nmol/l) and 6 μl nuclease-free water (total reaction
volume 25 μl). Primers for Kcnj11, Abcc9 and reference
genes (Actb, Hprt1 and Hspa8) were designed and selected
as previously described [16]. The primers for Gfp were:
forward, CGGCGACGTAAACGGCCACA; reverse
CAGCTTGCCGGTGGTGCAGA. Reactions were run on
an ABI PRISM 7000 sequence detection system (Applied
Biosystems). The reaction cycle comprised an initial dena-
turation for 10 min at 95°C, followed by 40 cycles of 95°C/
15 s; 60°C/60 s. All DNA samples were run in triplicate.
Non-RT controls were included in each experiment to con-
firm the absence of genomic DNA contamination.
The 7000 System SDS Software (Applied Biosystems)
was used to acquire and analyse PCR data and derive cycle
threshold (Ct) values. The ΔCt method was used to trans-
form Ct values into relative quantities and the highest ex-
pression for each primer pair was set to one. The geNorm
software was used on the three reference genes to calculate
normalisation factors for each tissue. The relative expression
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KATP channel recordings from cardiac muscle fibres Mice
were killed by cervical dislocation. The heart was immedi-
ately removed into Tyrode solution containing (in mmol/l)
NaCl 140, KCl 5.4, CaCl2 1.8, MgCl2 1, glucose 11, HEPES
5 (pH 7.4) and 10 U/l heparin. The aorta was cannulated and
the heart was perfused in a Langerdorf-type apparatus with
perfusion buffer containing (in mmol/l) NaCl 120.4, KCl
14.7, KH2PO4 0.6, Na2HPO4 0.6, MgSO4 1.2, NaHCO3 4.6,
taurine 30, 2,3-butanedione monoxime 10, glucose 5.5, and
HEPES 10 (pH 7.0), for 4 min at a flow rate of 4 ml/min.
Ca
2+-free collagenase solution (2.4 mg/ml collagenase II
[Worthington, Cambridge Biosciences, Cambridge, UK] in
perfusion buffer) was perfused for 3–4 min, and then low-
Ca
2+ collagenase solution (40 μmol/l Ca
2+ in Ca
2+-free
collagenase solution) for 5–10 min.
The heart was then removed and cut into small pieces in
myocyte stopping buffer (10% calf serum and 12.5 μmol/l
CaCl2 in perfusion buffer). Cells were further dissociated by
gentle pipetting. Ca
2+ was re-introduced to myocytes by
incubating, spinning down, and re-suspending the cells in
myocyte stopping buffer with increasing concentrations of
CaCl2 added. Myocytes were plated on poly-L-lysine-coated
coverslips in high-K
+ Tyrode solution (20 mmol/l K-Tyrode
solution, in which 14.6 mmol/l NaCl was replaced by KCl).
KATP channel activity was recorded in inside-out mem-
brane patches excised from rod-shaped, Ca
2+-tolerant cells
using an EPC7 amplifier (List Electronik) at a constant
holding potential of –60 mV. The pipette solution contained
(in mmol/l): 140 KCl, 1.2 MgCl2, 2. CaCl2, 10 HEPES,
pH 7.4. The intracellular solution contained (in mmol/l):
155 KCl, 11 EGTA, 2 MgCl2,1C a C l 2,1 0H E P E S ,
pH 7.2, with MgATP as indicated. To control for possible
rundown or reactivation by MgATP, Ic was taken as the
mean of the current in control solution (I) before and after
ATP application. Concentration–response curves were fitted
with a modified Hill equation:
I=Ic ¼ 1= 1 þ MgATP ½  =IC50
h  
where [MgATP] is the concentration of MgATP and h is the
slope factor.
Cardiac MRI
Cardiac cine-MRI was performed as described [34–36].
Briefly, 12-week-old control and m-V59M mice were anaes-
thetised with 1.5% isoflurane in O2 and positioned supine in
a purpose-built cradle. ECG electrodes were inserted into
the forepaws and a respiration loop was taped across the
chest. The cradle was lowered into a vertical-bore, 11.7 T
MR system (Magnex Scientific, Oxford, UK) with a 40 mm
birdcage coil (Rapid Biomedical, Würzburg, Germany) and
a Bruker console running Paravision 2.1.1 (Bruker Medical,
Ettlingen, Germany). A stack of contiguous 1 mm thick true
short-axis ECG and respiration-gated cine-FLASH images
(TE/TR 1.43/4.6 ms; 17.5° pulse; field of view 25.6×
25.6 mm; matrix size 256×256; voxel size 100×100×
1000 μm; 20–30 frames per cardiac cycle) were acquired
to cover the entire left ventricles. Long-axis two- and four-
chamber images were also acquired. Image analysis was per-
formed using ImageJ(NIH Image,Bethesda, MD, USA). Left
ventricular mass, volumes and ejection fractions were calcu-
lated as described [35, 36]. Wall thickness was measured at
enddiastoleand end systole inthe interventricular septumand
the left ventricular (LV) free wall in a mid LV slice.
Dobutamine stress MRI An intraperitoneal injection of
1.5 mg/kg of dobutamine was performed while mice were
still positioned in the scanner, as described by Song et al.
[37]. The heart rate typically increased within 2 min of the
injection, stabilised at 5 min and remained elevated for over
20 min. Once the heart rate had stabilised, three representa-
tive cine-FLASH MR images (basal, mid LV and apical)
were acquired at the same locations as were used before
dobutamine exposure. Changes in volumes and ejection
fraction are reported as the sum of these three slices. The
entire in vivo imaging protocol was performed in approxi-
mately 50 min. There were no obvious differences observed
between the three types of control mouse (WT, ROSA and
Mck-Cre) so the data were pooled.
Statistics
Data are expressed as mean±SEM. All n values refer to the
number of mice tested. Data were analysed using a repeated-
measures ANOVA (with genotype as a between-subject
factor and dobutamine treatment as a within-subject factor).
Differences were considered significant at p<0.05. Statistics
were performed using SPSS (IBM, Chicago, IL, USA).
Results
We used a Cre-lox approach in combination with the
muscle creatine kinase promoter (Mck-Cre) to selectively
target the Kir6.2-V59M mutant subunit to cardiac and
skeletal muscle [16]. This avoids any confounding effects
due to the high blood glucose concentration and severe
diabetes observed when Kir6.2-V59M is targeted to pan-
creatic beta cells [14].
The expression pattern of WTand mutant Kcnj11 mRNA
was assessed in control (WT, ROSA and Mck-Cre [14]) and
1198 Diabetologia (2012) 55:1195–1204m-V59M mice using semi-quantitative PCR (Fig. 1a). To
distinguish between WT and mutant mRNA we exploited
the fact that introduction of the V59M mutation removes a
unique BtsCI restriction site in the Kcnj11 cDNA. Thus, the
presence of two bands on the gel indicates WT Kcnj11
mRNA alone whereas three bands indicates the presence
of both WT and mutant (V59M) Kcnj11 mRNAs. Figure 1a
confirms that mRNA encoding Kir6.2-V59M is expressed
in the heart and skeletal muscle, but not the brain, of m-
V59M mice. As expected mutant mRNA is not expressed in
control (WT, ROSA and Mck-Cre) mice.
To determine the relative amount of Kcnj11 and Abcc9
expression in control and m-V59M mice we performed
quantitative PCR. Expression of Kcnj11, Abcc9 and Gfp
(encoding green fluorescent protein) mRNAs was expressed
relative to a panel of housekeeping genes (Actb, Hprt1 and
Hspa8). Figure 1b shows that there was no change in Kcnj11
mRNA expression in brain of m-V59M mice, but that
Kcnj11 expression was increased by about 90% in hearts
of m-V59M mice compared with controls. This increase can
be attributed to mRNA encoding Kir6.2-V59M, as shown
from the level of expression of Gfp (Fig. 1c), which lies
downstream of the mutated Kcnj11 gene and is transcribed
from the same promoter. This indicates that there is roughly
the same amount of WT and mutant Kcnj11 mRNAs. Thus,
at the RNA level this establishes the hemizygous m-V59M
mouse as a plausible model for human patients with iDEND
syndrome, all of who are heterozygotes [2, 3].
Despite the increase in total Kcnj11 mRNA, the overall
KATP channel density should remain relatively constant as
Abcc9 mRNA expression was unchanged in the heart
(Fig. 1d), and Kir6.2 is unable to traffic to the membrane
in the absence of SUR [38].
ATP sensitivity of KATP channels in V59M heart
Patch-clamp recordings of isolated ventricular myocytes
from m-V59M mice revealed that the magnitude of the KATP
current recorded in inside-out patches in the absence of
nucleotides was not significantly different in WTand mutant
myocytes, being 287±75 pA (n014) and 453±99 pA (n0
14) respectively (p∼0.2). No currents were detected in cell-
attached patches on either WT or mutant myocytes.
The ATP sensitivity of the native muscle KATP channel
was significantly reduced compared with control mice
(Fig. 2a-d). The half-maximal inhibitory concentration
(IC50) shifted from 13±1 μmol/l (n014 patches, four mice)
for WT channels to 62±7 μmol/l (n010 patches, n03 mice)
for channels recorded from m-V59M myocytes (Fig. 2e).
This indicates that the mutant protein is present in the heart.
The concentration–inhibition relationship was best fitted
with a single Hill equation.
Cardiac MRI
Cardiac MRI was performed on 12-week-old control and m-
V59M mice (Fig. 3a–c). Body weight and resting heart rates
under anaesthesia were similar between control and m-
V59M mice (Fig. 4a, Table 1). In vivo measurements of left
ventricular (LV) ejection fractions, volumes and cardiac
outputs identified no differences between groups (Fig. 4b–c,
Table 1). Left ventricular mass and septal wall thickness were
also similar in control and m-V59M mice (Fig. 4f, Table 1).
Fig. 1 Kcnj11 expression in the heart. a Kcnj11 expression in tissue
isolated from ROSA, WT, Mck-Cre and m-V59M mice. WT, but not
mutant (V59M), Kcnj11 cDNA is cut by the restriction enzyme BtsCI:
the presence of two bands thus indicates the presence of the WT gene
only and three bands indicates both WT and mutant genes. Data are
representative of experiments on seven ROSA, four m-V59M, four
WT and four Mck-Cre mice. sk1, quadriceps muscle; sk2, triceps
muscle; sk3, diaphragm. b,c Quantitative PCR showing expression of
Kcnj11 in heart and brain (b) and Gfp in heart (c) of control (grey bars,
n05) and m-V59M mice (white bars, n05), relative to a panel of
housekeeping genes.
*p<0.05 against controls. d Quantitative PCR
showing expression of Abcc9 in heart of control (grey bars, n05) and
m-V59M mice (white bars, n05), relative to a panel of housekeeping
genes. No significant differences were seen
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peritoneal administration of 1.5 mg/kg dobutamine resulted in
a significant elevation in heart rate within 5 min of injection
(Figs 3 and 4d, Table 2). Dobutamine increased LV ejection
fractions and cardiac outputs, and reduced end diastolic and
endsystolicvolumes(Fig.4a–e,Table2).Italsoincreasedend
diastolic and end systolic septal wall thickness (Fig. 4f). Sim-
ilar responses to dobutamine stress were observed in control
and m-V59M mice (Fig. 4, Table 2).
Discussion
Our results suggest that m-V59M mice have normal hearts.
There were no gross morphological differences observed
between images of m-V59M and control hearts, and no
differences in a variety of measures of cardiac function
under resting conditions, including heart rates, LV ejection
fractions, end diastolic, end systolic and stroke volumes,
cardiac outputs, mass and wall thickness. In response to
dobutamine stress, heart rates, ejection fractions, cardiac
outputs and wall thickness increased, while end diastolic
and end systolic volumes decreased, as expected, but there
were still no differences between the two sets of mice. Thus,
we conclude that expression of the Kir6.2-V59M subunit in
the heart had no marked effect on heart function, even under
stress conditions. This is in marked contrast to knockout of
Kir6.2, which reduces the capacity to cope with cardiac
stress [24, 25].
A similar effect was found in a different KATP channel
gain-of-function mouse model [31]. Although this mutation
produced a 40-fold reduction in the ATP sensitivity of the
cardiac KATP channel, these mice had normal electrocardio-
grams and their hearts showed no gross physiological or
morphological problems. In contrast to our mice, however,
ΔΝ30,K185Q mice showed an impaired response to β-
adrenergic receptor stimulation [32]. This difference may
be because Rajashree and colleagues used isolated perfused
hearts and isoproterenol infusion, while we injected a bolus
of dobutamine into the living animal and measured in vivo
cardiac function using MRI. The isolated hearts beat at a
much lower intrinsic rate than in the whole animal, presum-
ably due to loss of sympathetic innervation and circulating
hormones: this likely explains why the heart rates of both
control and mutant mice in our experiments were similar to
those of Rajashree and colleagues in the presence of β-
adrenergic agonists, but were faster under resting conditions
[32]. Studies of action potential duration and cardiac func-
tion in isolated hearts from m-V59M mice would help
address whether this idea is correct and, potentially, might
identify differences in cardiac function between m-V59M
and control mice. Nevertheless, the lack of in vivo differences
suggeststhatinvitro experiments would yield the sameresult.
Electrophysiological studies showed that the IC50 for
ATP inhibition of KATP channels in ventricular myocytes
isolated from m-V59M mice (62 μmol/l) is similar to that
found for skeletal muscle (67±11 μmol/l) [16]a n df o r
Kir6.2-V59M/SUR2A channels heterologously expressed
in Xenopus oocytes (79±18 μmol/l). This provides evidence
that the Kir6.2-V59M subunit is present at the protein level
and indicates that the m-V59M mouse provides a valid
model for the heterozygous state of patients carrying the
Kir6.2-V59M mutation.
The lack of an obvious effect of the Kir6.2-V59M muta-
tion on cardiac function resembles that found for skeletal
muscle [16]. In both tissues, the mutant subunits are
expressed in approximately equal amounts to WT subunits
and form KATP channels with reduced ATP sensitivity—yet
Fig. 2 ATP sensitivity of cardiac KATP channels in control and m-
V59M mice. a–d KATP channel currents recorded at −60 mV in inside-
out patches from control (a,c) or m-V59M (b,d) cardiac myocytes. The
solid bar indicates application of 30 μmol/l or 100 μmol/l MgATP, as
indicated. The dashed line indicates the zero current potential. Hori-
zontal bars indicate 5 s. e Mean relationship between MgATP concen-
tration and KATP current (I), expressed relative to that in the absence of
nucleotide (Ic), for WT (white circles, n014 patches, four mice) and m-
V59M (black circles, n010 patches, three mice) channels. The lines are
drawn to equation 1, with the following parameters: WT (IC500
13 μmol/l, h01.2); m-V59M (IC50059 μmol/l, h01.1)
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ence of Kir6.2-V59M in nerve or pancreatic beta cells has
profound functional effects [14, 16]. This difference may be
a consequence of the different SUR subunits that comprise
the cardiac/skeletal muscle (Kir6.2/SUR2A) and the beta
cell/brain KATP channels (Kir6.2/SUR1). As discussed
above, different subtypes of cardiac myocyte have different
types of SUR subunit, with SUR1 being the prevalent sub-
type in atrial cells and SUR2A in ventricular cells [29]. Our
experiments primarily measure ventricular function (Kir6.2/
SUR2A subunits). Similarly, although a significant amount
of SUR1 mRNAwas found in fast twitch muscle, SUR2A is
the most abundant subunit expressed in all skeletal muscle
fibre types tested [39].
The origin of the different metabolic sensitivities of Kir6.2/
SUR2A and KirR6.2/SUR1 channels is unclear. When heter-
ologouslyexpressedinXenopusoocytes,Kir6.2-V59M/SUR1
channels are opened by metabolic inhibition whereas Kir6.2-
V59M/SUR2Achannels are not [16]. Precisely whythis is the
case is still not clear. However, while ATP block and MgADP
activation are not different for the two types of channel,
MgADP can reduce ATP inhibition of Kir6.2-V59M/SUR1
channels but not Kir6.2-V59M/SUR2A channels [16]. This
suggests that the molecular basis of differential metabolic
sensitivity of SUR1 and SUR2A channels is due to altered
nucleotide handling by the different sulfonylurea receptors.
There is good evidence that atrial KATP channels are com-
posed of Kir6.2/SUR1 channels [20], which show a greater
metabolic sensitivity than Kir6.2/SUR2A channels. Thus we
might have expected an effect of the Kir6.2-V59M mutation
on atrial function. As this was not seen, it suggests that atrial
KATP channels are largely closed in the resting and stressed
states and that their activation by the Kir6.2-V59M mutation
is not sufficient to affect ventricular function. We did not
measure atrial function directly. Nevertheless, we did not
identify changes in atrial size on long-axis MR scout images,
anditislikelythatgrosschanges inatrialfunctionwouldhave
ledtosecondarychangesinventricularfunction,whichwedid
not observe. In the future it would be interesting to perform
additional studies to look at atrial function directly.
Fig. 3 Cardiac MRI of control and m-V59M mice. In vivo MRI on 12-
week-old control and m-V59M mice. Typical in vivo cine-MRI images
acquired in short-axis (base, mid-LV and apex) and long-axis (two-
chamber) views at end diastole and end systole prior to and after
administration of dobutamine. Morphology and function of the control
mouse heart (a) were similar to the m-V59M mouse heart (b). Scale
bar, 5 mm. c The multi-slice segmentation method for calculation of
LV myocardial mass and cavity volume at end diastole and end systole
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and ABCC8 (SUR1) genes that cause neonatal diabetes
in human patients have been linked to cardiac dysfunction
[2, 3, 6]. It is important to be cautious when extrapolating
from mouse models to humans, especially in the case of the
heart (the mouse heart rate is far higher). Nevertheless, the
detailed study reported here suggests that this is probably
because gain-of-function KATP channel mutations do not
cause cardiac abnormalities, rather than heart problems
existing, but being undetected. They also suggest that patients
are unlikely to develop cardiac problems when adrenaline
(epinephrine) levels rise (during exercise or in stressful states)
as a consequence of the expression of a gain-of-function KATP
channel in the heart. However, it remains possible that im-
paired cardiac function may be exacerbated under ischaemic
Fig. 4 Cardiac function and morphology in control and m-V59M
mice. Heart rate (a), ejection fraction (b) and end diastolic, end systolic
and stroke volume (c) were similar in control (grey bars, n06) and m-
V59M (white bars, n05) mouse hearts. Heart rate and ejection fraction
(d) increased, while end diastolic and end systolic volume (e)d e -
creased under dobutamine stress. The response to dobutamine stress
was similar in control (grey bars, n06) and m-V59M (white bars, n05)
mouse hearts. f At rest there was no difference in septal wall thickness
between control and m-V59M mice (lower bars). Dobutamine in-
creased end diastolic and end systolic septal wall thickness (upper
bars), p<0.05. A similar response to dobutamine was observed in
control (grey bars, n06) and m-V59M (white bars, n05) mice
Table 1 Cardiac morphology and function assessed by MRI
Variable Control (n06) m-V59M (n05)
Heart rate (beats/min) 464±23 468±65
Ejection fraction (%) 60±2 62±1
End diastolic volume (μl) 50±4 47±4
End systolic volume (μl) 20±2 18±2
Stroke volume (μl) 30±2 29±3
Cardiac output (ml/min) 14±1 14±2
LV mass (mg) 73±6 73±4
Body weight (g) 25±2 26±2
Data are means±SEM for 12-week-old control (n06) and m-V59M
(n05) mice
Data were analysed using a Student’s t test; no significant differences
between control and mV59M mice were identified
Table 2 Changes in cardiac function under dobutamine stress assessed
by MRI
Variable Change under dobutamine stress (%)
Control (n06) m-V59M (n05)
Heart rate 8±2
* 6±4
*
Ejection fraction 12±3
*** 15±2
***
End diastolic volume −28±6
** −20±5
**
End systolic volume −48±9
*** −52±7
***
Stroke volume −14±6 −1±6
Cardiac output 8±2
* 5±2
*
Data are means±SEM for 12-week-old control (n06) and m-V59M
(n05) mice
Data were compared with those acquired before stress using a
repeated-measures ANOVA (with genotype as a between-subject factor
and dobutamine treatment as a within-subject factor)
*p<0.05,
**p<0.01and
***p<0.001 against pre-dobutamine data; there
were no significant differences between control and m-V59M mice
1202 Diabetologia (2012) 55:1195–1204conditions or could arise in patients with neonatal dia-
betes as a secondary consequence of poor control of glucose
homeostasis. Studies of ischaemia–reperfusion in vivo and in
isolated hearts from m-V59M mice might be valuable in this
respect.
Finally, sulfonylureas are now first-line therapy for neo-
natal diabetes, with glibenclamide being the usual choice
[40]. The choice of sulfonylurea used for type 2 diabetes
therapy has long been debated [41–43]. In particular, there
has been concern that some drugs, such as glibenclamide,
may interact adversely with cardiac (SUR2A-containing)
KATP channels. KATP channel activation plays an important
role in cardiac ischaemic preconditioning [7, 9], and this
effect is prevented by glibenclamide [44]. Patients with
neonatal diabetes routinely require much higher sulfonyl-
urea doses than patients with type 2 diabetes and may be
expected to take the drugs for far longer. Our demonstration
that cardiac function is unimpaired in m-V59M mice argues
that mutant cardiac KATP channels remain closed and thus it
may not be necessary to use a sulfonylurea drug that cross-
reacts with cardiac KATP channels to treat the patient's
diabetes. This might be beneficial, as it would allow open-
ing of cardiac KATP channels during ischaemia and enable
ischaemic preconditioning.
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